Xeris, a leading UK-based healthcare firm, has received a patent allowance for its Keveyis treatment for hypokalaemic periodic paralysis, a rare condition affecting approximately 50,000 people worldwide. The patent allowance, granted by the UK Intellectual Property Office, will remain in place until 2039, cementing Xeris' market dominance in the treatment's sector.
Xeris Hails Patent Allowance for Keveyis Treatment until 2039
UKPulse Health DeskUK-based healthcare firm Xeris receives patent allowance for its Keveyis treatment for hypokalaemic periodic paralysis, securing its market dominance until 2039.
- Xeris secures patent allowance for Keveyis treatment
- Patent protection for Keveyis treatment remains in place until 2039
- Xeris aims to expand Keveyis treatment globally
Why this matters: This development is crucial for patients suffering from hypokalaemic periodic paralysis, as it ensures Xeris' Keveyis treatment will remain available to them without generic competition. Additionally, this reinforces the UK's position as a hub for innovative healthcare solutions.
What this means for you: What this means for you: As a UK resident, this news may bring some relief to those affected by hypokalaemic periodic paralysis, ensuring continued access to a treatment they rely on.